...
首页> 外文期刊>Clinical infectious diseases >Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance
【24h】

Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance

机译:抗菌药物开发的经济诱因:文献综述和抗菌药物耐药性的跨大西洋工作组的考虑

获取原文
获取原文并翻译 | 示例
           

摘要

The Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) in 2015 was tasked with exploring economic incentives for antibacterial drug development and providing recommendations for potential global implementation. Due to the continual decline of pharmaceutical companies investing in new antibiotic development and the rise in antimicrobial resistance, there is an urgent need to examine market mechanisms that are appropriate to encourage small, medium, and large companies to reinvest in this space. This review provides a summary of the various models that have been proposed and highlights positions posed by several policy documents, peer-reviewed publications, organization proposals, and government-sponsored reviews. The findings support a form of a de-linkage model and a combination of push and pull incentive mechanisms. This level of consensus could culminate in global coordination of incentives that strike a balance of rewarding innovation and ensuring appropriate antibiotic use.
机译:2015年跨大西洋抗菌素耐药性工作组(TATFAR)的任务是探索促进抗菌药物开发的经济诱因,并为潜在的全球实施提供建议。由于投资于新抗生素开发的制药公司的持续下降和抗菌素耐药性的上升,迫切需要研究适合鼓励小型,中型和大型公司在这一领域进行再投资的市场机制。这篇综述总结了已经提出的各种模型,并重点介绍了一些政策文件,同行评审的出版物,组织建议以及政府赞助的评审所提出的立场。这些发现支持一种脱链模型以及推拉激励机制的组合。这种共识水平最终可能会在全球范围内协调激励措施,从而在奖励创新和确保适当使用抗生素之间取得平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号